Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis

NCT01093885 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Systemic Sclerosis
Scleroderma

Interventions

DRUG: Ambrisentan

Sponsor

University of Pennsylvania

Collaborators

[object Object]